Substance / Medication

Brimonidine

Overview

Active Ingredient
brimonidine
RxNorm CUI
134615

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Evidence on the neuroprotective properties of brimonidine in glaucoma.
Scuteri Damiana, Bagetta Giacinto, Nucci Carlo et al. · Prog Brain Res · 2020
PMID: 32988470Meta-Analysis
Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies.
Cantor Louis B, Liu Ching-Chi, Batoosingh Amy L et al. · Curr Med Res Opin · 2009
PMID: 19469697Meta-Analysis
Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma.
Einarson T R, Kulin N A, Tingey D et al. · Clin Ther · 2000
PMID: 11192141Meta-Analysis
A Split-face Randomized Comparative Study of Efficacy of Pulsed Dye Laser, Topical Brimonidine Tartrate, and Their Combination for Treatment of Post-acne Erythema.
Omar Shaimaa I, Al-Jarem Yehia Farouk, El Banaa Alshaimaa Mohamed et al. · Adv Skin Wound Care · 2025
PMID: 40833510RCT
Pupillometry changes following ocular administration of brimonidine in patients experiencing acute migraine attack.
Karakaya Caner, Kilic Seyma, Yildirim Isik · Medicine (Baltimore) · 2025
PMID: 40660595RCTFull text (PMC)
Effect of brimonidine on visual indices in patients with acute optic neuritis: A single blind randomized clinical trial.
Arish Mohammed, Sargazi Meisam, Dakkali Mohammad Sedigh et al. · Mult Scler Relat Disord · 2024
PMID: 39383685RCT
Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Freeman William R, Bandello Francesco, Souied Eric et al. · Ophthalmol Retina · 2023
PMID: 36906177RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Brimonidine (substance)
SNOMED CT
372547000
UMLS CUI
C0525227
RxNorm CUI
134615

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.